α-<((R,S)-acetylthio)methyl>benzenebutanoic acid | 116112-44-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-<((R,S)-acetylthio)methyl>benzenebutanoic acid
• 英文别名: 2-[(acetylthio)methyl]-4-phenylbutanoic acid；2-[Acetylthiomethyl]-4-phenylbutyric acid；4-Phenyl-2-[acetylthio-methyl]butyric acid；2-(acetylsulfanylmethyl)-4-phenylbutanoic acid
• CAS: 116112-44-8
• 化学式: C₁₃H₁₆O₃S
• 分子量: 252.334
• InChiKey: XGJBZKQKCKGFHL-UHFFFAOYSA-N

物化性质

• 沸点：
  405.4±38.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-<((R,S)-acetylthio)methyl>benzenebutanoic acid 在 N-甲基吗啉 、 sodium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 (2S)-4-methylsulfanyl-2-[[(2R)-4-phenyl-2-(sulfanylmethyl)butanoyl]amino]butanoic acid
  参考文献：
  名称：

  Mercaptoacyl aminoacid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives

  摘要：

  A broad series of N-(3-mercaptoacyl) amino acid derivatives was evaluated for their ability to inhibit atriopeptidase (neutral endopeptidase, EC 3.4.24.11) in vitro and in vivo. Structural parameters studied were (i) the substituent on the 2-position of the 3-mercaptopropionyl moiety, (ii) the amino acid component, (iii) the S-terminal derivative, and (iv) the C-terminal derivative. Optimum activity was observed for derivatives of methionine and S-alkylcysteines. N-[3-Mercapto-2(S)-[(2-methylphenyl)methyl]-1-oxopropyl]-L-methionine was identified as a highly effective inhibitor of atriopeptidase meriting evaluation as a potential cardiovascular therapeutic agent.

  DOI：

  10.1021/jm00041a026
• 作为产物：
  描述：

  1,1-dimethylethyl 2-(2-phenylethyl)-3-oxobutanoate 在 正丁基锂 、 二异丙胺 、 三氟乙酸 作用下， 反应 74.67h， 生成 α-<((R,S)-acetylthio)methyl>benzenebutanoic acid
  参考文献：
  名称：

  Mercaptoacyl aminoacid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives

  摘要：

  A broad series of N-(3-mercaptoacyl) amino acid derivatives was evaluated for their ability to inhibit atriopeptidase (neutral endopeptidase, EC 3.4.24.11) in vitro and in vivo. Structural parameters studied were (i) the substituent on the 2-position of the 3-mercaptopropionyl moiety, (ii) the amino acid component, (iii) the S-terminal derivative, and (iv) the C-terminal derivative. Optimum activity was observed for derivatives of methionine and S-alkylcysteines. N-[3-Mercapto-2(S)-[(2-methylphenyl)methyl]-1-oxopropyl]-L-methionine was identified as a highly effective inhibitor of atriopeptidase meriting evaluation as a potential cardiovascular therapeutic agent.

  DOI：

  10.1021/jm00041a026

文献信息

• Beta-thiopropionyl-amino acid derivatives and their use as
  申请人：SmithKline Beecham P.L.C.

  公开号：US06156774A1

  公开（公告）日：2000-12-05

  Mercapto amino acid derivatives of formula (I), wherein R is hydrogen, a salt-forming cation of a in vivo hydrolysable ester-forming group; R.sub.1 is selected from (a) and (b) in which A is a monocyclic aryl or heteroaryl ring and B is a monocyclic aryl, alicyclic or heterocyclic ring, C and D are independently --Z.sub.p --(CR.sub.8 CR.sub.9).sub.q -- or --(CR.sub.8 CR.sub.9).sub.q --Z.sub.p -- where p is 0 or 1, q is 0 to 3 provided that p+q in C is not 0, R.sub.8 and R.sub.9 are independently hydrogen or (C.sub.1-6)alkyl or together represent oxo and Z is O, NR.sub.10 or S(O).sub.x where R.sub.10 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl and x is 0-2, and wherein C and D are linked ortho to one another on each of the rings A and B in formula (b); R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl--(CH.sub.2).sub.m --X--(CH.sub.2).sub.n, heterocyclyl or heterocyclyl--(CH.sub.2).sub.m --X--(CH.sub.2).sub.n, where m is 0 to 3, n is 1 to 3 and X is O or S(O).sub.x where x is 0-2 or a bond; R.sub.4 is hydrogen or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.r, where r is 2 to 5; for use in treatment of bacterial infections in humans or animals by administration in combination with a .beta.-lactam antiobiotic.

  公式(I)中的巯基氨基酸衍生物，其中R为氢，是体内可水解酯形成基团的盐形成阳离子；R.sub.1是从(a)和(b)中选择的，其中A是单环芳基或杂环芳基环，B是单环芳基、脂环或杂环环，C和D分别为--Z.sub.p --(CR.sub.8 CR.sub.9).sub.q --或--(CR.sub.8 CR.sub.9).sub.q --Z.sub.p --，其中p为0或1，q为0到3，前提是C中的p+q不为0，R.sub.8和R.sub.9独立地为氢或(C.sub.1-6)烷基，或一起代表氧代和Z为O、NR.sub.10或S(O).sub.x，其中R.sub.10为氢、(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基，x为0-2，且C和D在公式(b)中的环A和B上相互连接；R.sub.2为氢、(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢、(C.sub.1-6)烷基，可选地被高达三个卤原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯烃基，(C.sub.2-6)炔烃基，芳基，芳基--(CH.sub.2).sub.m --X--(CH.sub.2).sub.n，杂环基或杂环基--(CH.sub.2).sub.m --X--(CH.sub.2).sub.n，其中m为0到3，n为1到3，X为O或S(O).sub.x，其中x为0-2或一个键；R.sub.4为氢或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.r，其中r为2到5；用于治疗人类或动物的细菌感染，通过与β-内酰胺抗生素联合给药。
• N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
  申请人：Merck & Co., Inc.

  公开号：US05629343A1

  公开（公告）日：1997-05-13

  Novel N-(mercaptoacyl)peptidyl compounds are useful as inhibitors of matrix metalloendoproteinases which degrade major components of articular cartilage and basement membranes causing degenerative diseases such as arthritis, periodontal disease, corneal ulceration, are described. For example, N-(2-thiomethyl-4-phenyl-butanoyl)-L-leucinamide was prepared and its inhibitory activity against stromelysin was tested in vitro.

  新型N-(巯基酰)肽类化合物可作为基质金属蛋白酶抑制剂，这些金属蛋白酶会降解关节软骨和基底膜的主要成分，导致退行性疾病，如关节炎、牙周病、角膜溃疡等。例如，已制备N-(2-硫甲基-4-苯基丁酰)-L-亮氨酰胺，并在体外测试了其对溶解酶的抑制活性。
• Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0361365A1

  公开（公告）日：1990-04-04

  Compounds of the formula wherein X is inhibit the action of neutral endopeptidase. As a result, such compounds produce diuresis, natriuresis, and lower blood pressure as well as being useful in the treatment of congestive heart failure, relieving pain, and diarrhea when administered to a mammalian host.

  其中X的化合物抑制中性内肽酶的作用。因此，这些化合物产生利尿、排钠和降低血压的效果，同时在治疗充血性心力衰竭、缓解疼痛和腹泻时对哺乳动物宿主有用。
• Hydantoin derivative as metalloprotease inhibitor
  申请人：FUJIREBIO INC.

  公开号：EP0640594A1

  公开（公告）日：1995-03-01

  A hydantoin derivative represented by formula (I): wherein the all symbols are defined in the disclosure. The hydantoin derivative has an inhibitory activity on metalloprotease and hence is useful as analgesic and cardiovascular drug.

  一种以化学式(I)表示的噻唑烷酮衍生物：其中所有符号均在披露中定义。该噻唑烷酮衍生物具有对金属蛋白酶的抑制活性，因此可用作镇痛和心血管药物。
• Ophthalmic compositions for treating ocular hypertension
  申请人：——

  公开号：US20040054213A1

  公开（公告）日：2004-03-18

  This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

  本发明涉及使用有效的钾通道阻滞剂或其制剂治疗青光眼和其他导致患者眼内压升高的疾病。本发明还涉及使用这些化合物为哺乳动物（特别是人类）的眼提供神经保护作用。